DIOSynVax is revolutionizing vaccine antigen payload development
DIOSynVax customises vaccine antigen design to maximise the protection that vaccines can provide worldwide against existing and future viruses. Grounded firmly in virus structure and evolution, our method is patent protected, combining computational biology with in vitro and in vivo validation, selecting the best Vaccine Antigen Payload (VAP) candidates while growing a reservoir of data that continually improves our designs.
Collaborators
We partner with leading organisations to advance innovative vaccine solutions and protect global health
Latest News
Stay informed with the latest updates from DIOSynVax, including advancements in our vaccine development programs, strategic partnerships, and industry insights.
June 2025
Our Next-Generation Influenza vaccines have now demonstrated efficacy and safety in animal models and are ready for human trials.
April 2025
This bilateral project is supported by Innovate UK and Enterprise Singapore, as part of the UK-Singapore Collaborative R&D Call.
March 2025
This innovative technology aims to protect against a wide array of influenza strains.